Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Collaboration revenue — Total by Quarter
Collaboration revenue — Total ($M) ($M)
Moderna Collaboration revenue — Total: $15M in Q2 2026, up 275.0% from a year earlier.
Latest, Q2 2026
15
Period ended Jun 30, 2026
Change on a year earlier
+275.0%
4 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
28
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up collaboration revenue — Total
Cite this data
StockData. (2026). Moderna Collaboration revenue — Total ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rev-collab
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.